Remove 2023 Remove Safety Remove Treatments
article thumbnail

FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced cSCC

The Dermatology Digest

The resubmission has been accepted as a complete response to the FDA’s December 2023 complete response letter (CRL) and the FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2024. The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.

article thumbnail

And the Winners Are…PeDRA Announces 2023 Grant Recipients

The Dermatology Digest

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Fenbendazole Joe Tippens Protocol: A Simple Step-by-Step Guide (2023)

Aesthetics Advisor

Disclaimer: We in no way endorse the Joe Tippens Cancer Protocol as a cure for cancer, and as always, you should consult your physician before starting any new medications or treatment plans. However, it is also being used by humans in a cancer treatment method known as the Joe Tippens Protocol. What Is Fenbendazole? chemotherapy?

Therapy 69
article thumbnail

ASDSA Calls on States to Protect Patients from Counterfeit Neurotoxins

The Dermatology Digest

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69
article thumbnail

And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines

The Dermatology Digest

Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Hugel resubmitted its application in October 2022 and was denied approval again in 2023. Now, there are six neuromodulators approved for cosmetic use in the U.S.: and Europe.

article thumbnail

Exploring the Future of Beauty at the International Esthetics Cosmetics Skincare Conference 2023 in Las Vegas

New Age Spa Institute

Las Vegas, known as the entertainment capital of the world, welcomed beauty professionals and skin care enthusiasts from across the globe for the highly anticipated International Esthetics Cosmetics Skincare Conference (IECSC) 2023. body treatments. Let’s dive into the captivating highlights of this exceptional conference.

article thumbnail

The Changing Vitiligo Treatment Landscape? 

The Dermatology Digest

Pandya, MD, Director, Pigmentary Disorders Clinic, Palo Alto Foundation Medical Group, Sunnyvale, California; and Adjunct Professor of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas “This is the most exciting time of my career when it comes to treatment of vitiligo. 2020;396(10244):110-120.